The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

[1]  I. Holen,et al.  Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model , 2010, International journal of cancer.

[2]  P. Dong,et al.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.

[3]  Mark B. Jones,et al.  Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. , 2008, Journal of the National Cancer Institute.

[4]  G. Hortobagyi,et al.  Staging of breast cancer in the neoadjuvant setting. , 2008, Cancer research.

[5]  I. Holen,et al.  Exploring the anti-tumour activity of bisphosphonates in early breast cancer. , 2008, Cancer treatment reviews.

[6]  E. Winer,et al.  Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Hans-Peter Sinn,et al.  Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast , 2008, Breast Cancer Research.

[8]  A. Buzdar.  Preoperative chemotherapy treatment of breast cancer—A review , 2007, Cancer.

[9]  A. Schneeweiss,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Coleman.  Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. , 2007, Clinical breast cancer.

[12]  I. Holen,et al.  Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates , 2006, Nature Clinical Practice Oncology.

[13]  Norman Wolmark,et al.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Andreas Makris,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Kurosumi.  Significance and problems in evaluations of pathological responses to neoadjuvant therapy for Breast Cancer , 2006, Breast cancer.

[16]  H. Tsuda,et al.  Unargued issues on the pathological assessment of response in primary systemic therapy for breast cancer. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[17]  L. Carey,et al.  American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome. , 2005, Journal of the National Cancer Institute.

[18]  G. Hortobagyi,et al.  Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Walker,et al.  Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. , 2002, Clinical breast cancer.

[20]  A. Vincent-Salomon,et al.  Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. V. D. van de Velde,et al.  Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Wickerham,et al.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Coindre,et al.  Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. , 1996, British Journal of Cancer.

[26]  B. Asselain,et al.  Neoadjuvant chemotherapy in operable breast cancer. , 1991, European journal of cancer.